Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Repligen Cp (RGEN)

Repligen Cp (RGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,255,107
  • Shares Outstanding, K 54,429
  • Annual Sales, $ 670,530 K
  • Annual Income, $ 128,290 K
  • 60-Month Beta 0.98
  • Price/Sales 12.92
  • Price/Cash Flow 39.07
  • Price/Book 4.90
Trade RGEN with:

Options Overview Details

View History
  • Implied Volatility 53.73% ( -3.41%)
  • Historical Volatility 58.45%
  • IV Percentile 72%
  • IV Rank 61.97%
  • IV High 68.10% on 05/24/22
  • IV Low 30.32% on 07/27/21
  • Put/Call Vol Ratio 0.04
  • Today's Volume 251
  • Volume Avg (30-Day) 94
  • Put/Call OI Ratio 1.11
  • Today's Open Interest 4,087
  • Open Int (30-Day) 6,340

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate 0.73
  • Number of Estimates 6
  • High Estimate 0.80
  • Low Estimate 0.66
  • Prior Year 0.79
  • Growth Rate Est. (year over year) -7.59%

Price Performance

See More
Period Period Low Period High Performance
1-Month
137.21 +23.93%
on 05/12/22
170.79 -0.44%
on 05/27/22
+12.53 (+7.96%)
since 04/27/22
3-Month
137.21 +23.93%
on 05/12/22
203.73 -16.54%
on 03/01/22
-22.06 (-11.48%)
since 02/25/22
52-Week
137.21 +23.93%
on 05/12/22
327.32 -48.05%
on 09/23/21
-11.41 (-6.29%)
since 05/27/21

Most Recent Stories

More News
Repligen (RGEN) Up 3.6% Since Last Earnings Report: Can It Continue?

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

RGEN : 170.04 (+6.83%)
Repligen Appoints Dr. Konstantin Konstantinov to Board of Directors

WALTHAM, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of...

RGEN : 170.04 (+6.83%)
Repligen Corporation to Present at Upcoming Investor Conferences

WALTHAM, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology...

RGEN : 170.04 (+6.83%)
2 Top Healthcare Stocks to Buy for the Long Haul

These two stocks are posting strong results despite the broader market sell-off.

MRNA : 147.66 (+8.73%)
RGEN : 170.04 (+6.83%)
Will Repligen's (RGEN) COVID Woes Be Offset by Product Demand?

The declining pace of COVID-19 vaccination programs is likely to hurt Repligen's (RGEN) revenue growth rate in 2022. However, the strong core business is likely to offer a respite.

ALKS : 30.54 (+4.02%)
ANGN : 1.5000 (+13.64%)
RGEN : 170.04 (+6.83%)
SESN : 0.5300 (+1.47%)
Repligen (RGEN) Q1 Earnings and Sales Beat Estimates, Stock Up

Repligen (RGEN) reports encouraging first-quarter results with both sales and earnings beating estimates. RGEN also reduced its financial guidance for 2022

VRTX : 273.73 (+1.51%)
ANGN : 1.5000 (+13.64%)
RGEN : 170.04 (+6.83%)
DCPH : 11.46 (+7.20%)
Why Repligen Is Up More Than 10% Today

A stronger-than-expected earnings report calls months of the stock's weakness into question.

RGEN : 170.04 (+6.83%)
Repligen (RGEN) Beats Q1 Earnings and Revenue Estimates

Repligen (RGEN) delivered earnings and revenue surprises of 27.78% and 12.45%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

RGEN : 170.04 (+6.83%)
INO : 1.9900 (+13.71%)
Repligen Reports First Quarter 2022 Financial Results and Updates Full Year 2022 Financial Guidance

—Record revenue of $206.4 million for the quarter, and year-over-year growth of 45% as reported and 48% at constant currency —Organic revenue...

RGEN : 170.04 (+6.83%)
2 Reasons to Buy Repligen, and 1 Reason to Sell

Management has executed its strategy well, but a potential risk is looming.

RGEN : 170.04 (+6.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Repligen Corporation is a leading provider of advanced bioprocessing technologies and solutions used by large biopharmaceutical companies and contract manufacturing organizations for manufacturing biologic drugs, such as monoclonal antibodies (mAbs) and gene therapies. Repligen earns revenues from the...

See More

Key Turning Points

3rd Resistance Point 185.44
2nd Resistance Point 178.12
1st Resistance Point 174.08
Last Price 170.04
1st Support Level 162.72
2nd Support Level 155.39
3rd Support Level 151.35

See More

52-Week High 327.32
Fibonacci 61.8% 254.70
Fibonacci 50% 232.27
Fibonacci 38.2% 209.83
Last Price 170.04
52-Week Low 137.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar